Why Is AML So Fatal? Understanding the Aggressive Nature and Challenges of Acute Myeloid Leukemia

The phrase "Acute Myeloid Leukemia" (AML) often carries a heavy weight, and for good reason. Many people wonder, "Why is AML so fatal?" The stark reality is that AML is an aggressive blood cancer, and its high fatality rate stems from a complex interplay of factors including its rapid progression, the development of resistant cancer cells, and the inherent challenges in treating such a formidable disease. I've seen firsthand, through conversations with patients and their families, how devastating a diagnosis of AML can be. It strikes quickly, often catching people off guard, and its relentless nature demands immediate and aggressive intervention. This isn't a slow-moving illness; it's a whirlwind that can drastically alter a person's life in a matter of weeks or months.

At its core, AML is a cancer of the bone marrow, the spongy tissue inside our bones where blood cells are made. In AML, the bone marrow starts producing abnormal myeloid cells, often called "blasts." These immature cells don't mature into healthy white blood cells, red blood cells, or platelets. Instead, they multiply uncontrollably, crowding out the normal blood-forming cells. This overabundance of blasts is what leads to the serious complications associated with AML, and it’s a primary reason why this particular leukemia can be so dangerous.

So, why is AML so fatal? The answer isn't a single one, but a constellation of factors that make it a formidable opponent. Let's delve into these reasons, exploring the biology of AML, the complexities of its treatment, and the ongoing challenges that contribute to its grim statistics. Understanding these elements is crucial not only for medical professionals but also for patients, families, and anyone seeking to grasp the gravity of this disease.

The Aggressive Biology of AML: A Race Against Time

One of the most significant contributors to AML's fatality is its inherent aggressiveness. Unlike some other forms of cancer that might grow and spread slowly, AML is characterized by rapid proliferation of cancerous cells. This means that without prompt and effective treatment, the disease can progress very quickly, leading to life-threatening complications in a short period.

The myeloid lineage is responsible for creating various types of blood cells, including white blood cells that fight infection, red blood cells that carry oxygen, and platelets that help blood clot. When these cells go awry in AML, the body's ability to perform these vital functions is severely compromised. The accumulation of blasts in the bone marrow disrupts the production of healthy blood cells, leading to:

Anemia: A shortage of red blood cells means less oxygen is delivered to the body's tissues and organs. This can cause extreme fatigue, weakness, shortness of breath, and pallor. Without adequate red blood cells, vital organs, particularly the heart and brain, can be stressed and begin to fail.
Infections: The lack of functional white blood cells leaves the body highly vulnerable to infections. Even common bacteria or viruses can become life-threatening for an AML patient. The compromised immune system is one of the most immediate and dangerous consequences of the disease, and recurrent, severe infections can be a major cause of morbidity and mortality.
Bleeding: A deficiency in platelets impairs the blood's ability to clot. This can lead to easy bruising, nosebleeds, bleeding gums, and, more dangerously, internal bleeding, particularly in the brain or gastrointestinal tract. This risk of hemorrhage is a constant and serious threat.

The speed at which these deficiencies develop and the severity of their impact underscore why AML is so fatal. The body is rapidly overwhelmed by the malfunctioning cells, and the downstream effects on essential bodily functions are profound and immediate. It's truly a race against time from the moment of diagnosis.

The Role of Genetic Mutations: Driving the Aggression

The aggressive nature of AML is not arbitrary; it's driven by underlying genetic mutations within the developing myeloid cells. These mutations are like faulty instruction manuals for the cells, telling them to grow uncontrollably and preventing them from maturing into functional blood cells. There are many different genes that can be mutated in AML, and the specific combination of mutations can significantly influence how aggressive the disease is and how it responds to treatment.

Some common genetic abnormalities associated with AML include:

Chromosomal Translocations: These are breaks and rearrangements of chromosomes (the structures that carry our genes). For instance, the Philadelphia chromosome (a translocation between chromosomes 9 and 22) is famously associated with Chronic Myeloid Leukemia (CML), but other translocations are common in AML and often confer a poor prognosis. The specific translocation can create new, abnormal proteins that drive cancer growth.
Mutations in FLT3, NPM1, CEBPA, and IDH1/2 genes: These genes play crucial roles in cell growth, differentiation, and survival. Mutations in these genes can lead to increased cell proliferation, resistance to cell death (apoptosis), and a block in maturation, all of which contribute to the rapid progression of AML.

The presence of certain mutations is a strong indicator of prognosis. For example, FLT3 mutations, while offering potential targets for new therapies, are often associated with a higher risk of relapse and poorer outcomes. Conversely, NPM1 mutations, especially in the absence of FLT3 mutations, can sometimes indicate a better prognosis. This complex genetic landscape is why AML treatment needs to be highly individualized, based on the specific genetic profile of the patient's leukemia.

From a clinical perspective, identifying these mutations early is paramount. It allows oncologists to stratify patients into different risk groups—low, intermediate, or high risk—which guides treatment decisions. A patient with a high-risk genetic profile will often require more intensive therapy, including potentially a stem cell transplant, from the outset, because their leukemia is inherently more likely to be resistant to standard chemotherapy.

Challenges in Treatment: Battling a Shifting Target

The fight against AML is fraught with challenges, and these difficulties are central to understanding why it remains so fatal. Even with advancements in medical science, treating AML is far from straightforward.

The Need for Immediate and Intensive Therapy

Given AML's rapid nature, treatment must often begin immediately after diagnosis. This typically involves intensive chemotherapy designed to kill as many leukemia cells as possible. The goal is to achieve remission, meaning that the number of leukemia cells in the bone marrow is too low to be detected and does not cause symptoms. However, this intensive chemotherapy comes with significant side effects.

Chemotherapy, by its nature, doesn't just target cancer cells; it also affects rapidly dividing healthy cells, such as those in the bone marrow, hair follicles, and digestive tract. This leads to:

Myelosuppression: A severe drop in healthy blood cell counts (white blood cells, red blood cells, and platelets). This makes patients profoundly vulnerable to infections and bleeding, often requiring hospitalization for extended periods in protective environments with supportive care like blood transfusions and antibiotics.
Nausea, vomiting, and mouth sores: Common side effects that can severely impact a patient's quality of life and ability to eat.
Hair loss and fatigue: Debilitating symptoms that add to the physical and emotional toll of treatment.

The delicate balance between eradicating leukemia cells and managing these severe side effects is a constant challenge. Oncologists must carefully monitor patients, adjusting doses and providing supportive care to navigate this difficult terrain. For some patients, particularly older individuals or those with significant co-existing health problems, the toxicity of intensive chemotherapy can be too much to bear, forcing difficult decisions about the aggressiveness of treatment.

Relapse and Resistance: The Elusive Nature of AML

One of the most disheartening aspects of AML is its tendency to relapse. Even after achieving remission, leukemia cells can lie dormant, or a small population of cells might have developed resistance to the chemotherapy. These resistant cells can then multiply, leading to a return of the disease, often months or years later. This is a key reason why AML is so fatal; the cancer proves incredibly difficult to eradicate completely.

The development of drug resistance is a complex biological process. Leukemia cells, through random mutations or by adapting to the treatment environment, can develop ways to survive the chemotherapy drugs that would otherwise kill them. This might involve:

Pumping drugs out of the cell: Some cells develop mechanisms to actively expel chemotherapy drugs, preventing them from reaching their targets inside the cell.
Altering drug targets: The proteins or pathways that chemotherapy drugs are designed to attack can be altered, making the drugs ineffective.
Repairing drug-induced damage: Cancer cells can become better at repairing the damage that chemotherapy causes to their DNA.
Evading the immune system: Leukemia cells can also learn to hide from or disable the body's immune system, which could otherwise help in clearing them.

When AML relapses, it is often more difficult to treat than the initial presentation. The remaining leukemia cells may be inherently more resistant, and the patient may be weaker and less able to tolerate further aggressive therapies. This scenario underscores the insidious nature of AML and highlights why so many patients succumb to the disease.

The Challenge of Targeting Specific Leukemia Cells

AML is not a single entity but a heterogeneous group of diseases, meaning it can manifest differently from one patient to another. This heterogeneity is partly due to the wide array of genetic mutations that can occur. While this offers opportunities for personalized medicine, it also presents a significant challenge. A treatment that is highly effective against one type of AML might be ineffective against another.

The ideal scenario in cancer treatment is to target the cancer cells specifically while sparing healthy cells. However, AML cells originate from the body's own blood-forming cells, making it difficult to find targets that are exclusively present on leukemia cells and not on normal tissues. This is why many current treatments are still broadly cytotoxic, affecting healthy cells along with the cancerous ones.

Recent breakthroughs in understanding the molecular underpinnings of AML have led to the development of targeted therapies. Drugs that inhibit specific mutated proteins, like FLT3 inhibitors or IDH inhibitors, have shown promise in certain patient populations. However, the complexity of AML means that often, not all leukemia cells carry the same mutations, and some subclones may persist even after targeted therapy, leading to relapse. The ongoing research is focused on identifying more specific targets and developing combination therapies that can overcome this resistance.

The Role of Stem Cell Transplantation: A High-Stakes Option

For many AML patients, especially those with high-risk disease or who have relapsed, a stem cell transplant (also known as a bone marrow transplant) is the most viable option for a potential cure. This procedure replaces the patient's diseased bone marrow with healthy stem cells from a donor (allogeneic transplant) or, in some cases, their own previously collected healthy stem cells (autologous transplant, though less common for AML).

The rationale behind a stem cell transplant is twofold:

To allow for very high-dose chemotherapy or radiation: Before receiving new stem cells, the patient undergoes intense chemotherapy and/or radiation to eradicate any remaining leukemia cells. This dose of therapy would be too toxic without a replacement for the bone marrow.
To introduce a new immune system: In an allogeneic transplant, the donor's immune system can recognize and attack any residual leukemia cells (this is called the graft-versus-leukemia effect), offering an additional layer of anti-cancer activity.

While a stem cell transplant offers the best chance of cure for some patients, it is a high-risk procedure with significant potential complications:

Graft-versus-host disease (GVHD): In allogeneic transplants, the donor's immune cells can attack the recipient's healthy tissues and organs. This can range from mild skin rashes to severe, life-threatening damage to the liver, gut, and lungs.
Infections: The patient's immune system is severely suppressed after the conditioning regimen and before the new stem cells engraft, leaving them highly susceptible to severe infections.
Organ toxicity: The high-dose chemotherapy and radiation can cause damage to organs like the heart, lungs, and kidneys.
Relapse: Despite the intense treatment, some patients still relapse after a transplant.

The decision to pursue a stem cell transplant is therefore complex, weighing the potential for cure against the significant risks involved. It requires a meticulous workup to ensure the patient is fit enough for the procedure and that a suitable donor can be found. The success of a transplant hinges on many factors, including the patient's age and overall health, the specific type of AML, the donor match, and the expertise of the transplant center. The fact that even this aggressive treatment doesn't guarantee a cure for everyone underscores why AML remains such a challenging and often fatal disease.

The Impact of Age and Comorbidities: A Delicate Balance

A critical factor contributing to the high fatality rate of AML is the age of the patient and the presence of other health conditions, known as comorbidities. AML affects people of all ages, but it is diagnosed more frequently in older adults. Unfortunately, older patients often have a more difficult time tolerating the intensive treatments required for AML, and they tend to have a poorer prognosis.

Several reasons contribute to this:

Reduced tolerance to chemotherapy: As people age, their bodies may not be as resilient. Organ function, particularly of the heart, kidneys, and liver, may be less robust, making them more vulnerable to the toxic side effects of chemotherapy.
Increased risk of comorbidities: Older individuals are more likely to have pre-existing conditions like heart disease, diabetes, or kidney problems. These conditions can complicate AML treatment, increasing the risk of treatment-related complications and making it harder to achieve treatment goals.
Genetic differences in leukemia: Some research suggests that AML in older adults may have different underlying genetic mutations that make it inherently more difficult to treat or more prone to relapse.

For many older patients, the risks associated with intensive chemotherapy might outweigh the potential benefits. In such cases, oncologists may opt for less intensive treatment regimens, which are generally better tolerated but are less likely to achieve a complete and long-lasting remission. The goal shifts from attempting a cure to managing the disease and maintaining quality of life for as long as possible. This often involves palliative care, symptom management, and supportive therapies rather than aggressive disease-modifying treatments.

The challenge for clinicians is to individualize treatment plans not just based on the AML's biology but also on the patient's overall health and ability to withstand therapy. It's a difficult conversation, but crucial for respecting the patient's wishes and ensuring the best possible outcome within the constraints of their health status.

Diagnosis Delays and Access to Care: Missed Opportunities

While not inherent to the biology of AML itself, delays in diagnosis and disparities in access to expert care can significantly impact outcomes and contribute to the perception of AML as a highly fatal disease. Because the early symptoms of AML—fatigue, unexplained bruising, frequent infections—can be vague and easily mistaken for less serious conditions, diagnosis can sometimes be delayed.

When symptoms are attributed to other causes, such as the flu, stress, or aging, precious time can be lost. AML progresses rapidly, and a delay of even a few weeks can mean the disease has become more advanced and potentially harder to treat. This highlights the importance of vigilance and seeking medical attention for persistent or concerning symptoms.

Furthermore, access to specialized cancer centers with expertise in hematologic malignancies is critical for optimal AML care. These centers have access to the latest diagnostic tools, clinical trials, and multidisciplinary teams experienced in managing complex cases. Patients treated at community hospitals, while receiving good care, might not have the same breadth of options or the same level of specialized experience available to them.

Disparities in healthcare access based on socioeconomic status, geographic location, or insurance coverage can also lead to delayed diagnosis or suboptimal treatment. Ensuring that all patients, regardless of their background, have equitable access to timely diagnosis and expert care is a crucial step in improving AML outcomes and reducing its fatality.

The Psychological and Emotional Toll: A Battle Beyond the Physical

It's essential to acknowledge that the battle with AML extends far beyond the physical manifestations of the disease and its treatment. The psychological and emotional toll on patients and their families is immense, and this can indirectly impact the ability to cope with and recover from the illness.

Receiving an AML diagnosis, especially given its aggressive nature, can trigger intense feelings of fear, anxiety, and uncertainty. The rapid onset of the disease, the intensive and often debilitating treatment, and the unpredictable nature of the prognosis can be overwhelming. Patients may struggle with:

Fear of death and dying: Given the high fatality rate, this is a pervasive concern.
Loss of control: The medical team often takes over many aspects of daily life, leading to a feeling of powerlessness.
Anxiety about treatment side effects and future relapse: The specter of complications and the possibility of the cancer returning are constant worries.
Depression and feelings of hopelessness: The grueling nature of treatment and the uncertainty can lead to significant emotional distress.
Strain on family relationships and support systems: The demands of caregiving can be taxing, and the emotional burden is shared by loved ones.

The presence of strong psychosocial support, including counseling, support groups, and spiritual care, is vital. Addressing these emotional needs can empower patients, improve their resilience, and enhance their ability to adhere to treatment plans. While not directly causing AML's fatality, the immense psychological burden can hinder recovery and reduce the effectiveness of medical interventions. A holistic approach that addresses both the physical and emotional aspects of the disease is therefore indispensable.

Frequently Asked Questions About AML Fatality

Why does AML relapse so often?

AML relapses frequently due to the inherent resilience and adaptability of leukemia cells, coupled with the limitations of current treatment strategies. Even after successful initial treatment that clears detectable leukemia cells, a small population of dormant or minimally active cancer cells, often referred to as minimal residual disease (MRD), can persist. These cells might be genetically different or have developed mechanisms to evade the immune system or resist therapy.

The process of drug resistance is multifaceted. Leukemia cells can acquire new mutations during treatment, allowing them to survive chemotherapy. They might develop sophisticated mechanisms to pump drugs out of the cell, alter the drug's target within the cell, or become more adept at repairing DNA damage inflicted by the chemotherapy. Furthermore, AML is a heterogeneous disease, meaning that even within a single patient's leukemia, there can be multiple subclones of cells with different genetic profiles. A treatment might be effective against one subclone but leave another untouched, allowing the resistant cells to proliferate and eventually lead to relapse.

The intense nature of AML treatment, while aiming to eradicate the disease, can also inadvertently create selective pressure that favors the survival of resistant cells. It's a complex biological battle where the cancer cells are constantly evolving. The goal of ongoing research is to identify more potent and specific therapies that can eliminate even these elusive resistant populations or to develop strategies that prevent resistance from emerging in the first place.

Is AML always fatal?

No, AML is not always fatal. While it is a serious and aggressive cancer with a high fatality rate, significant advancements in diagnosis and treatment have improved survival rates, particularly for certain patient groups. The outcome for an individual with AML depends on a multitude of factors, including the specific subtype of AML, the presence of particular genetic mutations, the patient's age and overall health, their response to initial treatment, and access to specialized care.

For younger patients with favorable genetic mutations, or those who achieve a deep remission and are eligible for a stem cell transplant, the chances of long-term survival and even cure can be substantial. Clinical trials are continuously exploring new drug combinations, targeted therapies, and immunotherapies that are showing promise in overcoming resistance and improving outcomes for a broader range of AML patients. The field is dynamic, and while challenges remain, the outlook for AML is steadily improving, offering hope where there was once very little.

Why is childhood AML often more curable than adult AML?

Childhood AML generally has higher cure rates compared to adult AML for several key reasons. Firstly, children's bodies are typically more robust and can tolerate the intensive chemotherapy regimens required for AML treatment better than older adults. This means they can often receive the full intended doses of life-saving drugs without as many severe dose-limiting toxicities.

Secondly, childhood AML, as a group, often presents with different genetic and molecular characteristics that are more responsive to standard therapies. For instance, certain chromosomal translocations that are common in pediatric AML, such as t(8;21) or the Philadelphia chromosome in some cases, are associated with better prognoses and respond well to chemotherapy. In contrast, adult AML tends to be more genetically complex and heterogeneous, often driven by mutations that confer resistance to treatment.

Finally, children often benefit from highly coordinated, multidisciplinary care within specialized pediatric oncology centers. These centers are at the forefront of research, clinical trials, and best practice protocols for childhood cancers, leading to a more standardized and aggressive approach to treatment. While adult AML is also benefiting from advances, the biological differences and treatment tolerance often give childhood AML a significant advantage in terms of curability.

What are the most important factors influencing AML survival?

The prognosis for Acute Myeloid Leukemia (AML) is influenced by a complex interplay of factors, but some stand out as particularly critical in determining survival rates. Understanding these factors is essential for both medical teams and patients.

1. Molecular and Cytogenetic Abnormalities: This is arguably the most significant factor. The specific genetic mutations and chromosomal abnormalities present in the leukemia cells can dramatically impact how aggressive the AML is and how it will respond to therapy. Based on these findings, AML is categorized into risk groups: favorable, intermediate, and unfavorable. Patients with favorable-risk genetics have a significantly better prognosis and higher chances of long-term survival, often achievable with standard chemotherapy. Conversely, unfavorable-risk genetics are associated with a higher likelihood of relapse and poorer survival, frequently necessitating more aggressive treatments like stem cell transplantation.

2. Age and Performance Status: A patient's age is a major determinant of outcome. While AML can affect anyone, it is more common in older adults. Older patients generally have a harder time tolerating the aggressive chemotherapy required for AML, and they are more likely to have other health issues (comorbidities) that can complicate treatment and increase the risk of life-threatening side effects. A patient's "performance status"—a measure of their general health and ability to perform daily activities—is also a key indicator. Patients who are fitter and have a better performance status are more likely to tolerate intensive therapy and achieve remission.

3. Response to Initial Therapy: How well the leukemia responds to the first round of chemotherapy is a strong predictor of long-term survival. Achieving a complete remission (CR) after the induction chemotherapy phase is a crucial milestone. Patients who achieve a CR have a much better outlook than those who do not. Furthermore, the depth of remission, often assessed by looking for minimal residual disease (MRD) using highly sensitive molecular tests, is also important. Patients who clear MRD are less likely to relapse.

4. Availability of Stem Cell Transplantation and Donor Match: For patients with intermediate or unfavorable-risk AML, a stem cell transplant (SCT) is often the only potentially curative option. The availability of a suitable donor (a matched sibling or an unrelated donor) and the patient's fitness for the demanding SCT procedure are therefore critical factors in their survival. The success of SCT also depends on factors like the donor type and the specific transplant protocol used.

5. Patient's Overall Health and Comorbidities: Beyond age, the presence of other chronic health conditions, such as heart disease, lung disease, kidney problems, or diabetes, can significantly impact a patient's ability to withstand AML treatment and their overall prognosis. These comorbidities can limit treatment options or increase the risk of complications, thereby affecting survival.

These factors are not considered in isolation. Oncologists use sophisticated prognostic models that integrate multiple aspects of the patient and their disease to guide treatment decisions and provide the most accurate assessment of survival likelihood. The ongoing research in understanding AML biology and developing novel therapies continues to refine these prognostic indicators and, most importantly, improve survival outcomes.

What are the latest advancements in treating AML?

The landscape of Acute Myeloid Leukemia (AML) treatment is undergoing rapid evolution, driven by a deeper understanding of the disease's complex molecular underpinnings. These advancements are bringing new hope and improving outcomes for many patients. Here are some of the key areas of progress:

1. Targeted Therapies: Perhaps the most significant advancements have been in the development of targeted drugs that precisely attack specific molecular abnormalities found in leukemia cells. These drugs offer a more personalized approach, aiming to kill cancer cells while minimizing damage to healthy cells. Examples include:

FLT3 Inhibitors: Mutations in the FLT3 gene are common in AML and are associated with a poor prognosis. Drugs like gilteritinib and midostaurin have been approved to target these mutations, significantly improving outcomes for patients with FLT3-mutated AML, often used in combination with chemotherapy or as maintenance therapy after transplant.
IDH Inhibitors: Mutations in the IDH1 and IDH2 genes are also frequent in AML. Drugs like ivosidenib (for IDH1) and enasidenib (for IDH2) can help to differentiate leukemia cells into more mature, less harmful cells, thereby controlling the disease. These are particularly valuable for patients who cannot tolerate intensive chemotherapy.
Venetoclax and BCL-2 Inhibitors: Venetoclax, a BCL-2 inhibitor, has revolutionized the treatment of AML, especially for older or unfit patients. By blocking the BCL-2 protein, which prevents cancer cells from undergoing programmed cell death (apoptosis), venetoclax can induce rapid and deep remissions when combined with hypomethylating agents (like azacitidine or decitabine) or low-dose cytarabine. This combination therapy has become a new standard of care for many newly diagnosed AML patients who are not candidates for intensive chemotherapy.

2. Immunotherapies: Harnessing the power of the patient's own immune system to fight leukemia is another promising area. While still under intensive development for AML, several approaches are showing potential:

Antibody-Drug Conjugates (ADCs): These are antibodies that are linked to a potent chemotherapy drug. The antibody guides the drug directly to leukemia cells that express a specific surface marker, delivering a concentrated dose of toxicity to the cancer while sparing normal cells. Gemtuzumab ozogamicin is an example of an ADC used in AML.
Bispecific Antibodies: These engineered antibodies have two different binding sites: one that attaches to a leukemia cell and another that attaches to an immune cell (like a T-cell). This brings the immune cell into close proximity with the cancer cell, enabling the immune cell to attack and destroy it.
Chimeric Antigen Receptor (CAR) T-cell therapy: While highly successful in some other blood cancers like B-cell lymphomas, CAR T-cell therapy for AML has faced challenges due to the difficulty in finding suitable targets on AML cells that are also absent on vital normal tissues. However, research is ongoing to develop more effective CAR T-cell strategies for AML.

3. Advances in Stem Cell Transplantation: Stem cell transplantation remains a cornerstone of curative therapy for many AML patients. Recent improvements include better donor selection methods, reduced-intensity conditioning regimens that are less toxic, and improved management of complications like graft-versus-host disease (GVHD). New approaches also aim to enhance the graft-versus-leukemia effect while minimizing GVHD.

4. Improved Diagnostics and Monitoring: The ability to detect minimal residual disease (MRD) with highly sensitive techniques (like next-generation sequencing and flow cytometry) has become increasingly important. Detecting MRD allows clinicians to assess the effectiveness of treatment more accurately and to adjust therapy or initiate consolidation treatments to prevent relapse. This precision in monitoring is critical for optimizing patient care.

These advancements are transforming the treatment paradigm for AML, moving towards more individualized, less toxic, and more effective therapies. While AML remains a challenging disease, these innovations offer significant hope for improving survival rates and quality of life for patients.

In conclusion, the question "Why is AML so fatal?" unravels a complex tapestry of biological aggression, treatment challenges, and patient-specific factors. Its rapid progression, the development of drug resistance, the difficulty in eradicating all leukemia cells, and the significant toxicity of treatments all contribute to its formidable reputation. While the fight against AML is far from over, ongoing research and innovative therapies are continually pushing the boundaries, offering a brighter future for those affected by this challenging disease.

Why Is AML So Fatal? Understanding the Aggressive Nature and Challenges of Acute Myeloid Leukemia